Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database
- PMID: 16813650
- PMCID: PMC1533844
- DOI: 10.1186/1471-2407-6-174
Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database
Abstract
Background: The effect of current therapies in improving the survival of lung cancer patients remains far from satisfactory. It is consequently desirable to find more appropriate therapeutic opportunities based on informed insights. A molecular pharmacological analysis was undertaken to design an improved chemotherapeutic strategy for advanced lung cancer.
Methods: We related the cytotoxic activity of each of commonly used anti-cancer agents (docetaxel, paclitaxel, gemcitabine, vinorelbine, 5-FU, SN38, cisplatin (CDDP), and carboplatin (CBDCA)) to corresponding expression pattern in each of the cell lines using a modified NCI program.
Results: We performed gene expression analysis in lung cancer cell lines using cDNA filter and high-density oligonucleotide arrays. We also examined the sensitivity of these cell lines to these drugs via MTT assay. To obtain our reproducible gene-drug sensitivity correlation data, we separately analyzed two sets of lung cancer cell lines, namely 10 and 19. In our gene-drug correlation analyses, gemcitabine consistently belonged to an isolated cluster in a reproducible fashion. On the other hand, docetaxel, paclitaxel, 5-FU, SN-38, CBDCA and CDDP were gathered together into one large cluster.
Conclusion: These results suggest that chemotherapy regimens including gemcitabine should be evaluated in second-line chemotherapy in cases where the first-line chemotherapy did not include this drug. Gene expression-drug sensitivity correlations, as provided by the NCI program, may yield improved therapeutic options for treatment of specific tumor types.
Figures



Similar articles
-
Anticancer drug clustering based on proteomic profiles and a sensitivity database in a lung cancer cell line panel.Exp Ther Med. 2010 Jan;1(1):41-45. doi: 10.3892/etm_00000007. Epub 2010 Jan 1. Exp Ther Med. 2010. PMID: 23136590 Free PMC article.
-
In vitro simulation study of individualized chemotherapy in lung cancer.J Nippon Med Sch. 2007 Jun;74(3):217-22. doi: 10.1272/jnms.74.217. J Nippon Med Sch. 2007. PMID: 17625370
-
In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line.Lung Cancer. 2003 Jun;40(3):325-32. doi: 10.1016/s0169-5002(03)00072-2. Lung Cancer. 2003. PMID: 12781432
-
Rationale for non-platinum chemotherapy in advanced NSCLC.Oncology (Williston Park). 2001 Jul;15(7 Suppl 8):29-34. Oncology (Williston Park). 2001. PMID: 11497229 Review.
-
Gemcitabine in non-small cell lung cancer.Expert Opin Pharmacother. 2002 Jun;3(6):745-53. doi: 10.1517/14656566.3.6.745. Expert Opin Pharmacother. 2002. PMID: 12036414 Review.
Cited by
-
H-Prune through GSK-3β interaction sustains canonical WNT/β-catenin signaling enhancing cancer progression in NSCLC.Oncotarget. 2014 Jul 30;5(14):5736-49. doi: 10.18632/oncotarget.2169. Oncotarget. 2014. PMID: 25026278 Free PMC article.
-
The p44/wdr77-dependent cellular proliferation process during lung development is reactivated in lung cancer.Oncogene. 2013 Apr 11;32(15):1888-900. doi: 10.1038/onc.2012.207. Epub 2012 Jun 4. Oncogene. 2013. PMID: 22665061 Free PMC article.
-
Gene expression patterns within cell lines are predictive of chemosensitivity.BMC Genomics. 2008 Feb 8;9:74. doi: 10.1186/1471-2164-9-74. BMC Genomics. 2008. PMID: 18261237 Free PMC article.
-
Cancer association study of aminoacyl-tRNA synthetase signaling network in glioblastoma.PLoS One. 2012;7(8):e40960. doi: 10.1371/journal.pone.0040960. Epub 2012 Aug 31. PLoS One. 2012. PMID: 22952576 Free PMC article.
-
HSP27 modulates epithelial to mesenchymal transition of lung cancer cells in a Smad-independent manner.Oncol Lett. 2010 Nov;1(6):1011-1016. doi: 10.3892/ol.2010.190. Epub 2010 Sep 23. Oncol Lett. 2010. PMID: 22870103 Free PMC article.
References
-
- Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000;18:623–631. - PubMed
-
- Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–2103. - PubMed
-
- Eisen MB, Brown PO. DNA arrays for analysis of gene expression. Methods. 1999;303:179–205. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials